meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - maintenance (M)
2
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
endocrine therapy
androgen deprivation therapy (ADT)
abiraterone plus ADT
abiraterone plus docetaxel plus ADT
apalutamide plus ADT
darolutamide plus doxetaxel plus ADT
docetaxel plus ADT
enzalutamide
enzalutamide plus ADT
orteronel
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab plus enzalutamide
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
no study with result for this clinical condition